Anti Cathepsin B Market Size to Exceed USD 248.3 Mn by 2032

The Anti Cathepsin B Market, estimated at USD 199.2 Mn in 2025, is expected to exhibit a CAGR of 3.2% and reach USD 248.3 Mn by 2032.

The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.

The increasing research and development by key market players are expected to drive the global anti-cathepsin B market growth over the forecast period. For instance, on February 12, 2025, Thermo Fisher Scientific Inc., laboratory equipment supplier explained the research of antibodies that detect cathepsin B can be used in a variety of scientific applications, including western blot analysis, immunohistochemistry, immunocytochemistry, flow cytometry, and ELISA. These antibodies target cathepsin B in human, mouse, rat, and zebrafish samples. Cathepsin B polyclonal, monoclonal, and monoclonal recombinant antibodies were developed for rabbits, goats, and mice. These antibodies were verified for cathepsin B specificity by knockdown, relative expression, and cell processing. Find the right cathepsin B antibody for research needs.

Global Anti Cathepsin B Market- Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2025, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2025.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, faced problems regarding the transportation of drugs from one place to another.

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 had a negative impact on the global anti-cathepsin B market. For instance, according to an article published by the National Center for Biotechnology Information, on May 18, 2025, despite the great success of vaccines against SARS-CoV-2, the virus can still spread, as evidenced by the current circulation of the highly infectious Omicron variant. This further highlights the need to develop effective antiviral countermeasures. In the context of early preclinical studies, robust cell infection systems are needed to screen drug libraries for antiviral evaluation. In this study, researchers describe the deployment of a human glioblastoma cell line stably expressing ACE2 in an attempt to reduce the SARS-CoV-2 cytopathic effect (CPE). These glioblastoma cells are called U87.ACE2 expressed high levels of ACE2 and cathepsin B but had low levels of TMPRSS2 and cathepsin L in the cells. U87 ACE2 cells fused very efficiently and rapidly with cells expressing SARS-CoV-2 spikes.

Global Anti Cathepsin B Market: Key Developments

Increasing research is expected to drive the global anti-cathepsin B market growth.

For instance, on June 6, 2025, Molecular Systems Design & Engineering, London based journal explained the research as a method called Systematic Evolution of Ligands with Exponential Enrichment (SELEX) was used to generate and isolate new aptamers targeting cathepsin B. After 8 rounds of selection, the pool was sequenced and the 10 most frequent sequences and their corresponding reverse complementary sequences were further analyzed. Bioinformatics tools were used to analyze the binding affinity of aptamers to cathepsin B. After generating 3D structures for each aptamer, HADDOCK software was used to dock between them and cathepsin B. Molecular dynamics simulations and coupling free energy calculations with molecular mechanics generalized surface area (MM-GBSA) enabled the selection of new aptamers with the potential to target cathepsin B.

Browse 40 Market Data Tables and 48 Figures spread through 255 Pages and in-depth TOC on Global Anti Cathepsin B Market, by Product Type (Primary Antibodies, Proteins and Peptides, and Lysates), by Application (Cancer, Traumatic Brain Injury, Ebola Infection, Fertility Treatment, and Others), by Technique (Immunohistochemistry, Immunofluorescence, Western Blotting, ELISA, Flow Cytometry, and Others), by End User (Pharmaceutical Companies, and Academic and Research Institutes) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/anti-cathepsin-b-market-4169

Key Takeaways of the Global Anti-Cathepsin B Market:

• The global anti-cathepsin B market is expected to exhibit a CAGR of 3.2 % during the forecast period due to increasing research of anti cathepsin B. For instance, on December 22, 2025, National Center for Biotechnology Information stated that dysregulated inflammasome activation and interleukin (IL)-1β production is associated with several inflammatory disorders. Three different routes can lead to inflammasome activation: a canonical two-step, a non-canonical Caspase-4/5- and Gasdermin D-dependent, and an alternative Caspase-8-mediated pathway. Natriuretic Peptides (NPs), Atrial Natriuretic Peptide (ANP), and B-type Natriuretic Peptide (BNP), binding to Natriuretic Peptide Receptor-1 (NPR-1), signal by increasing cGMP (cyclic guanosine monophosphate) levels that, in turn, stimulate cGMP-dependent protein kinase-I (PKG-I).
• Among regions, North America is expected to be the dominant region in the global anti-cathepsin B market, owing to the increasing research and development of anti-cathepsin B. For instance, on April 14 2025 National Center for Biotechnology Information stated genetic fusion of propeptide of pro cathepsin B into the CDR3H region of Herceptin resulted in a humanized antibody inhibitor with high potency and specificity for human CTSB, providing a novel tool for probing the functions and roles of cathepsin B in physiology and pathophysiology and possibly leading to the development of new cathepsin B inhibitor-based diagnostics and therapeutics.
• The major players operating in the global anti-cathepsin B market include Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc, Abcam Plc.